Updates in TB

7,887 views
7,667 views

Published on

0 Comments
11 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
7,887
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
187
Comments
0
Likes
11
Embeds 0
No embeds

No notes for slide

Updates in TB

  1. 1. An overview and Updates in TB By Gamal Rabie Agmy , MD , FCCP Professor of Chest Diseases ,Assiut University ERS National Delegate of Egypt
  2. 2. Introduction *The increasing prevalence of tuberculosis in both immunocompetent and immunocompromised individuals in recent years makes this disease a topic of universal concern.
  3. 3. Epidemiology *The World Health Organization (WHO) estimates that each year more than 8 million new cases of tuberculosis occur and approximately 3 million persons die from the disease. *Ninety-five percent of tuberculosis cases occur in developing countries. *It is estimated that between 19 and 43% of the world's population is infected with Mycobacterium tuberculosis, the bacterium that causes tuberculosis infection and disease
  4. 4. Epidemiology     Most cases in the US are due to reactivation, especially amongst immigrants Highest risk of progression to active TB is within 2 years of seroconversion Increase in incidence in late 1980s-early 90s largely due to HIV Needs to be reported to the health department
  5. 5. Microbiology        Aerobic Bacillus (rod-shaped) Non-spore forming Non-motile Cell wall – mycolic acid – retains acid fast stain Growth - doubling time of 15-20 hrs. 3-8 weeks for growth on solid media
  6. 6. TB Skin Testing     PPD – purified protein derivative of tuberculin (antigenic) Delayed type hypersensitivity reaction PPD may not become “positive” until 3 months after exposure Boosting effect
  7. 7. Skin Test Interpretation  PPD >/= 5 mm: – HIV patients – Recent contacts of someone with TB – Fibrotic changes on CXR c/w prior TB – Organ transplant recipients – Immunosuppressed (includes patients receiving the equivalent of 15 mg/day or more of prednisone for one month or more)
  8. 8. Skin Test Interpretation  PPD >/= 10 mm: – Recent immigrants (< 5 years) from high prevalence areas (Eastern Europe, Latin America, Asia, Africa) – IV drug users – Residents and employees of high risk facilities (hospitals, nursing homes, homeless shelters, prisons) – Children < 4 years of age – Mycobacteriology lab personnel
  9. 9. Skin Test Interpretation  PPD >/= 10 mm: – People with medical conditions that place them at high risk for active TB Chronic renal failure  Diabetes mellitus  Silicosis  Leukemias/lymphomas  Carcinoma of the head/neck or lung  Weight loss > 10% of ideal body weight  Gastrectomy/jejunoileal bypass 
  10. 10. Skin Test Interpretation  PPD >/= 15 mm: – Low risk people – Routine tuberculin testing not recommended for low risk populations
  11. 11. Skin Test Intrepretation  False positives: – Non-tuberculous mycobacterial infection – BCG vaccination  False negatives: – HIV – Malnutrition – Steroid therapy – Recent infection
  12. 12. BCG  Bacille Calmette-Guerin vaccination: Live attenuated mycobacterial strain derived from M. bovis  Can yield false positives to PPD – less likely as time from vaccination increases  Reactions > 20 mm likely are true  CDC advises that the PPD be interpreted by the same guidelines (ignore the BCG history) 
  13. 13. Quantiferon Testing  Whole blood in vitro test: – Lymphocytes release IFN gamma in presence of 2 TB antigens   Will be positive in latent or active TB Advantages: – No error in interpretation – No follow-up in 48-72 hours – No boosting – Not affected by BCG
  14. 14. Quantiferon Testing  Disadvantages: – Must be processed within 12 hours of collection – False + with atypical mycobacteria – Too many indeterminate results with current version (Q-Gold) – May be less reliable in pregnant women, children, and immunocompromised – Does not distinguish between active and latent TB
  15. 15. Bacteriology Causative organism; Mycobacterium tuberculosis COMPLEX Stained with: -Modified gram stain: gram positive. -Carbolfuchsin stain: *Cold method(Kynon) *Hot(Zeil-Neelson) - Fluorescent dyes: rhodamine and auramine stains.
  16. 16. QUANTITATION SCALE FOR ACID-FAST BACILLUS SMEARS ACCORDING TO STAIN USED Carbolfuchsin (× 1,000) No AFB/300 fields Fluorochrome (× 250) No AFB/30 fields 1-2 AFB/300 fields 1-2 AFB/30 fields 1-9 AFB/100 fields 1-9 AFB/10 fields Quantity Reported No AFB seen Doubtful, repeat test Rare (1+) 1-9 AFB/10 fields 1-9 AFB/field Few (2+) 1-9 AFB/field 10-90 AFB/field Moderate (3+) > 9 AFB/field > 90 AFB/field Numerous (4+)
  17. 17. Zeil-Neelson Staining Wire 0.01 ml of specimen 200mm2 slide Oil immersion field 0.02mm Slide=10000 field=0.01ml specimen 10,000 organism/slide=1 AFB/field=1000,000 organism/ml 1000 organism/slide=1 AFB/10 field=100,000 organism/ml 100 organism/slide=1 AFB/100field=10,000 organism/ml
  18. 18. QUANTITATION SCALE FOR ACID-FAST BACILLUS SMEARS ACCORDING TO STAIN USED Carbolfuchsin (× 1,000) No AFB/300 fields Fluorochrome (× 250) No AFB/30 fields 1-2 AFB/300 fields 1-2 AFB/30 fields 1-9 AFB/100 fields 1-9 AFB/10 fields Quantity Reported No AFB seen Doubtful, repeat test Rare (1+) 1-9 AFB/10 fields 1-9 AFB/field Few (2+) 1-9 AFB/field 10-90 AFB/field Moderate (3+) > 9 AFB/field > 90 AFB/field Numerous (4+)
  19. 19. Cultures: - Lowenstein Jensen media: 6-8 weeks. -Bactec media: 2-8days. Radiolabelled 14c labelled palmitic acid -Mycobacterial growth indicator tube: Middbrook broth+o2 sensitive fluroscent sensor to indicate growth& bacilli can be identified by Gen Probe method at the same day of detection.
  20. 20. Diagnosis of Active TB       Acid fast stain of sputum Sputum AFB culture (culture needed for drug susceptibility) Radiographic imaging (CXR, CT) PCR/NAT Fluid Aspiration Tissue biopsy – higher yield than fluid
  21. 21. Direct Methods 1-Direct Microscopy (ZN, Kinyoun, Flurochrome). 2-Culture (Traditional, Rapid methods). 3- Detection of DNA or RNA of mycobacterial origin ( PCR, LAMP, TAA / NAA, LCR, Fast Plaque).
  22. 22. Direct Microscopic Examination *Hallmark of staining is Ziehl-Neelsen stained slides. Easiest & quickest diagnostic test. * Limited sensitivity (46-78%) but specificity is virtually 100%. * Centrifugation & flurochrome staining with UV microscopy markedly (auramine O) increase the sensitivity & a large number can be examined in a much shorter time.* *Chest 1969;95:1193
  23. 23. Direct Microscopic Examination 􀂄 ZN staining requires = 105 bacilli/ml. 􀂄 TB bacilli appear as straight/curved rods (1-4μ x 0.2-0.8μ) singly, in pairs or in clumps. 􀂄 The yield of microscopic examination correlates well with the extent of disease, the presence of cavitation, and the quality of specimen. 􀂄 It is a good marker for infectiousness & the response to the treatment.
  24. 24. Several approaches are being made to enhance the sensitivity of the smear microscopy : Concentration of sputum sample by centrifugation enhances sensitivity to almost 100%.* 􀂄 Treatment of sputum samples with Zwitterionic detergent, also known as C18 carboxyprophylbetaine( CB18) interferes with the innate buoyancy of the bacilli and enhances the result of sputum microscopy.** 􀂄 *J Clin Microbiol 1999;31: 2371 **J Clin Microbiol 1998;36: 1965
  25. 25. Traditional Culture 􀂄 More sensitive & can be positive even when bacterial load is low (10-100 bacilli/ml). 􀂄 Sensitivity 80-85%; Specificity 98%. 􀂄 Required for precise identification of causative organisms. 􀂄 3 Types of media are used: 􀂄 Egg based: LJ, Petragnani and ATS. 􀂄 Agar based: Middlebrook 7H10 or 7H11. Liquid based: Kirschner’s, Middlebrook 7H9. 􀂄 􀂄 Growth is slow and takes 6-8 weeks . There after the same length of time is required for complete identification & sensitivity testing.
  26. 26. Broth Based Rapid Culture Methods 􀂄 Micro colony detection on solid media. Radiometric (BACTEC). 􀂄 Septicheck AFB. 􀂄 􀂄 Mycobacterial growth indicator tubes (MGIT). 􀂄 Substantial improvement in time to detection & total number of positive cultures can be realized from using broth based systems.
  27. 27. Micro colony Detection on Solid Media 􀂄 Plates poured with thin layer of Middlebrook 7H11 agar medium are incubated and examined microscopically on alternate days for the first 2 days and less frequently thereafter. 􀂄 In less than 7 days micro-colonies of slow growing mycobacteria such as M.tb can be detected.
  28. 28. Micro colony Detection on Solid Media 􀂄 Plates poured with thin layer of Middlebrook 7H11 agar medium are incubated and examined microscopically on alternate days for the first 2 days and less frequently thereafter. 􀂄 In less than 7 days micro-colonies of slow growing mycobacteria such as M.tb can be detected.
  29. 29. BACTEC Growth is ascertained 􀂄 by liberation of 14CO2 as metabolized by mycobacteria & detected by BACTEC 460 instrument & reported in terms of growth index (GI) value
  30. 30. BACTEC 􀂄 Average time to recovery of M.tb from smear positive specimens is 8 days. 􀂄 When smear negative, culture positive samples are examined, mean time for detection is 14 days. 􀂄 More sensitive than traditional method.* 􀂄 Can also be used for drug susceptibility testing. *J Clin Microbiol 1994;32: 918-925
  31. 31. BACTEC 􀂄 A special procedure unique to BACTEC system for identification of M.tb complex is based on observation that p-nitro-α-acetylamino-βhydroxypropiophenone (NAP) will inhibit organisms belonging to M.tb complex while having little or no effects on other mycobacteria. Drawbacks : 􀂄 Cost. 􀂄 􀂄 Problem of disposal of radioactive waste.
  32. 32. Septicheck AFB 􀂄 Combines broth & solid media into a single device (biphasic culture approach). 􀂄 Contains 30ml of modified Middlebrook 7H9 broth in CO2 enriched culture bottle & a peddle with agar media- one side of peddle covered with Middlebrook 7H11; other side contains Middle brook 7H11 with NAP. 􀂄 Requires 3 weeks of incubation 􀂄 Advantage: Simultaneous detection of Mtb. NTM, other respiratory pathogen & even contaminant.
  33. 33. Mycobacterial Growth Indicator Tube (MGIT) Rapid Method. 􀂄 􀂄 Consists of round bottom tubes containing 4 ml of modified Middlebrook 7H9 broth which has an oxygen sensitive fluroscent sensor at the bottom.* 􀂄 When mycobacteria grow, they deplete the dissolved oxygen in the broth & allow the indicator to fluoresce brightly in a 365nm UV light. * J Clin Microbiol 1999;37: 748-752
  34. 34. Mycobacterial Growth Indicator Tube (MGIT) 􀂄 Positive signals are obtained in 10-12 days. 􀂄 MGIT can also be used as a rapid method for the detection of drug resistant strains of Mtb directly from acid-fast smear positive samples as well as from indirect drug susceptibility studies. Advantages over BACTEC 􀂄 Cheaper. 􀂄 􀂄 No problem of radioactive waste disposal. J Clin Microbiol 1999;37: 45-48
  35. 35. Detection and identification of mycobacteria directly from clinical samples Genotypic Methods : 􀂄 PCR 􀂄 LAMP 􀂄 TMA / NAA 􀂄 Ligase chain reaction 􀂄 Phenotypic Methods : 􀂄 FAST Plaque TB 􀂄
  36. 36. Polymerase Chain Reaction (PCR) 􀂄 Essentially PCR is a way to make millions of identical copies of a specific DNA sequence , which may be a gene, or a part of a gene, or simply a stretch of nucleotides with a known DNA sequence, the function of which may be unknown. 􀂄 A specimen that may contain the DNA sequence of interest is heated to denature double stranded DNA.
  37. 37. Polymerase Chain Reaction (PCR) 􀂄 Specific synthetic oligonucleotide primers bind to the unique DNA sequences of interest and a heat stable DNA polymerase (Thermus aquaticus) extends the primer to create a complete & complimentary strand of DNA. 􀂄 This process is repeated sequentially 25-40 times, thereby creating millions of copies of target sequence.
  38. 38. Polymerase Chain Reaction (PCR) Kd antigen (HSPs): 65 􀂄 Used earlier 􀂄 􀂄 Heat shock protein believed to be distinct from other bacterial HSPs. 􀂄 This gene is identical in all species of mycobacteria. 􀂄 Therefore unsuitable for detecting M.tb, particularly in areas where species like M.avium or M.kansasii are prevalent.
  39. 39. IS6110 : 􀂄 It is a transposon which are self replicating stretches of DNA. Function not known. 􀂄 􀂄 This sequence has been found in the M.tb complex organisms (M.tb, M.africanum, M.microti, M.bovis). 􀂄 IS6110 sequence generally occurs only once in M.bovis but is found as often as 20 times in certain strains of M.tb, thus offering multiple targets for amplification.
  40. 40. Polymerase Chain Reaction (PCR) 􀂄 With recent modification PCR can detect even a fraction of a bacilli. Role in pulmonary TB : 􀂄 􀂄 Detects nearly all smear +ve and culture +ve cases. 􀂄 Useful technology for rapid diagnosis of smear –ve cases of active TB. 􀂄 Able to identify 50-60% of smear -ve cases; this would reduce the need for more invasive approaches to smear ve cases.
  41. 41. Distinguish M.tb from NTM in smear +ve cases as IS6110 sequence is not found in NTM.* 􀂄 Should not be used to replace sputum microscopy. 􀂄 Sensitivity, specificity, & PPV for PCR is 83.5%, 99% & 94.2% respectively.** *Am Rev Respir Dis 1991; 144:1160 ** J Clin Microbiol 1999;31: 2049-2055
  42. 42. Polymerase Chain Reaction (PCR) 􀂄 Role in Extrapulmonary TB Limited Role 􀂄 􀂄 No comprehensive large series comparing the yield of PCR with other available approaches has been published. 􀂄 But at present, it is valuable adjunct in the diagnosis of TBM, pleurisy, pericardial TB & other condition in which yield of other tests are low.
  43. 43. Polymerase Chain Reaction (PCR) Disadvantages : 􀂄 Very high degree of quality control required. 􀂄 Variation from lab to lab remain significant. 􀂄 In pts. on ATT, PCR should not be used as an indicator of infectivity as this assay remains +ve for a greater time than do cultures.* 􀂄 Am J Respir Crit Care Med 1997;155: 1804-1854
  44. 44. High false +ve results in patients previously treated with ATT in contacts of sputum +ve active cases. High Cost. 􀂄 􀂄 So, better understanding of how to use these tests in conjunction with available clinical information is essential.* *Thorax 1992;47:690-694
  45. 45. LAMP* Loop-mediated isothermal 􀂄 amplification. 􀂄 It is a novel nucleic acid amplification method in which reagents react under isothermal conditions with high specificity, efficiency, and rapidity. 􀂄 LAMP is used for detection of M.tb complex, M.avium, and M.intracellulare directly from sputum specimens as well as for detection of culture isolates grown in a liquid medium (MGIT) or on a solid medium (Ogawa’s medium). *Iwamoto T et al J Clin Microbiol 2003;41 :2616-2619
  46. 46. LAMP 􀂄 This method employs a DNA polymerase and a set of four specially designed primers that recognize a total of six distinct sequences on the target DNA. 􀂄 Species-specific primers were designed by targeting the gyrB gene. 􀂄 Simple procedure, starting with the mixing of all reagents in a single tube, followed by an isothermal reaction during which the reaction mixture is held at 63°C. min incubation time.- 60 􀂄
  47. 47. LAMP 􀂄 Due to its easy operation without sophisticated equipment, it will be simple enough to use in: Small-scale hospitals, 􀂄 Primary care facilities 􀂄 􀂄 Clinical laboratories in developing countries. Difficulties : 􀂄 Sample preparation 􀂄 Nucleic acid extraction 􀂄 Cross-contamination. 􀂄
  48. 48. TMA / NAA Transcription Mediated Amplification 􀂄 (TMA). 􀂄 Nucleic Acid Amplification (NAA). 􀂄 These techniques use chemical rather than biological amplification to produce nucleic acid. 􀂄 Test results within few hours. 􀂄 Currently used only for respiratory specimens.
  49. 49. Ligase Chain Reaction 􀂄 It is a variant of PCR, in which a pair of oligonucleotides are made to bind to one of the DNA target strands, so that they are adjacent to each other. 􀂄 A second pair of oligonucleotides is designed to hybridize to the same regions on the complementary DNA.
  50. 50. Ligase Chain Reaction 􀂄 The action of DNA polymerase and ligase in the presence of nucleotides results in the gap between adjacent primers being filled with appropriate nucleotides and ligation of primers. 􀂄 It is mainly being used for respiratory samples, and has a high overall specificity and sensitivity for smear +ve and –ve specimens.
  51. 51. FAST Plaque TB 􀂄 It is an original phage based test. 􀂄 It uses the mycobacteriophage to detect the presence of M.tb directly from sputum specimens. 􀂄 It is a rapid, manual test, easy to perform and has a higher sensitivity than microscopy, in newly diagnosed smear +ve pts.* *Int J Tuberc Lung Dis 1998;2: 160
  52. 52. Indirect Methods Antibody detection : 􀂄 TB STAT-PAK 􀂄 ELISA 􀂄 India test TB 􀂄 Antigen detection : 􀂄 􀂄 TB MPB 64 patch test. Quantiferon-GOLD test. 􀂄 Biochemical Assays :(ADA, Bromide Partition, Gas Chromatography ). 􀂄
  53. 53. TB STAT-PAK Immuno-chromatographic test. 􀂄 􀂄 Has been evolved with a capability to differentiate between active or dormant TB infection in whole blood, plasma or serum. 􀂄 Its value in in disease endemic countries is yet to be ascertained.* *Eur Resp J 1995;8: 676
  54. 54. Antibody detection by ELISA. 􀂄 Several serodiagnostic tests, principally those using ELISA methodology for measurement of IgG Ab are available. 􀂄 38-Kd Ag provides serodiagnostic test with most favorable test characteristics described, but is limited by the lack of purified Ag. 􀂄 Serum IgG Ab are observed to rise during the first 3 months of therapy but fall after 12-16 months.
  55. 55. Antibody detection by ELISA. 􀂄 Other purified antigens to which antibodies are detected : 30 Kd protein antigen 􀂄 16 Kd heat-shock antigen Lipoarabinomannan(LAM) – LAM is a complex glycolipid associated with cell wall of mycobacteria & is produced in substantial quantities by growing M.tb. A60 antigen 􀂄 ES31/41 antigen 􀂄 􀂄 􀂄
  56. 56. Antibody detection by ELISA. 􀂄 IgM Ab levels have usually been found to be so low that their reliable measurement has been difficult. 􀂄 Serodiagnosis with crude Ag gives high false positive results. 􀂄 These tests lack specificity because polyclonal Ab are used. 􀂄 Use of monoclonal antibodies have increased their specificity.
  57. 57. Antibody detection by ELISA. 􀂄 It takes several months after diagnosis for patients with pulmonary TB to reach maximum antibody titers so that serodiagnosis appears to be more useful in chronic extrapulmonary disease (bone or joint) than in acute forms (miliary, TBM). 􀂄 Serodiagnosis also has limited utility in smear negative patients with minimal PTB; In pediatric TB & in disease endemic countries with high infection rates.
  58. 58. Antibody detection by ELISA. 􀂄 ELISA also has limited diagnostic potential in AIDS prevalent population.* 􀂄 Tests are expensive, require trained personnel & difficulty in distinguishing Mtb & NTM. 􀂄 Serologic tests have not yet demonstrated sufficient performance to warrant routine use in control programs. * Int J Tuberc Lung Dis 2000;4132: 5152-5388
  59. 59. Antibody detection by ELISA. 􀂄 Sensitivity and specificity of ELISA serodiagnostic tests using measurement of serum IgG Ab to selected mycobacterial Ag: Antigen Sensitivity Specificity 38 Kd 49-89 98-100 30 Kd 62-72 97-100 16 Kd 24-71 97-99 LAM 26-81 92-100 A60 71-100 71-95
  60. 60. Antibody detection by ELISA. 􀂄 The detection of mycobacterial antigens by immunoassay in clinical specimens with high & variable protein content is difficult. 􀂄 Detection in sputum presents even greater clinical problem because sputum is a nonhomogenous gel . 􀂄 False positive rates are high. 􀂄 Abandonment of this diagnostic tool.
  61. 61. Insta test TB 􀂄 It is a rapid in vitro assay for the detection of antibody in active TB disease using whole blood or serum. 􀂄 The test employs an Ab binding protein conjugated to a colloidal gold particle and a unique combination of TB Ags immobilized on the membrane.* *Tuberc. Lung Dis 1998;2: 541
  62. 62. TB MPB 64 patch test 􀂄 MPB 64 is a specific mycobacterial antigen for M.tb complex. 􀂄 This test becomes +ve in 3-4 days after patch application and lasts for a week. Specificity~100%, Sensitivity~98.1%.* 􀂄 􀂄 This promising test has been reported so far only in one setting in Philippines and needs to be carried out in other settings. *Ind J Tuberc Lung Dis 1998;2: 541
  63. 63. Quantiferon-GOLD 􀂄 Due to advances in molecular biology and genomics, an alternative has emerged for the first time in the form of a new class of in vitro assays that measure interferon (IFN-γ) released by sensitized T cells after stimulation by M. tuberculosis antigens. 􀂄 Measures immune reactivity to M.tb.
  64. 64. Quantiferon-GOLD 􀂄 Interferon-γ assays measure cellmediated immunity by quantifying IFN-γ released from sensitized T cells in whole blood/PBMCs incubated with TB antigens.
  65. 65. QuantiFERON-TB ® test (Cellestis, Australia – Commercially available. – Measures amount of IFN-γ produced. (ELISA) – FDA-approved for the detection of LTBI, 2001. ELISPOT assay (Oxford, UK) 􀂄 – Similar to QFT. – Measures number of reactive lymphocytes. – Not commercially available.
  66. 66. Quantiferon-GOLD Early assays employed PPD (same specificity problems as the TST). 􀂄 Newer assays (e.g., QFT-Gold) employ TB-specific antigens: ESAT-6 and CFP-10. 􀂄 Proteins encoded within the region of difference 1 of M.tuberculosis. 􀂄 Not shared with the BCG sub-strains and most NTM (except: M. kansasii, M. szulgai, M. marinum and nonpathogenic M.bovis).
  67. 67. Quantiferon-GOLD Improved specificity: able to distinguish between TB and NTM, BCG infection. 􀂄 Studies in contacts, HIV infected and children underway. 􀂄 Recommended for use in “ALL circumstances in which the tuberculin skin test is currently used”.* 􀂄 Includes contact investigations, immigrant evaluation, surveillance (e.g. healthcare workers). *Mazurek et al MMWR 2005;54:15
  68. 68. IGRAs Vs. TST IGRAs TST 􀂄 In vivo In vitro 􀂄 Single antigen 􀂄 Boosting 􀂄 patient visits 2 􀂄 Inter-reader variability 􀂄 Results in 2-3 days 􀂄 Read in 48-72 hrs 􀂄 􀂄 􀂄 Multiple antigens 􀂄 No boosting 􀂄 patient visit 1 􀂄 Minimal inter-reader 􀂄 variability 􀂄 Results in 1 day 􀂄 Stimulate w/i 12 hrs
  69. 69. IGRAs Vs. TST 􀂄 QFT-g vs. TST Agreement = 83.6%* 􀂄 Factors associated with discordance : – Prior BCG – Non-tuberculous mycobcateria immune reactivity – Site bias in reading TST – TB Treatment *Mazurek et al JAMA 2001;286:1740
  70. 70. Biochemical markers of Diagnosis Adenosine deaminase. (ADA) 􀂄 Bromide partition test. 􀂄 􀂄 Gas chromatography of mycobacterial fatty acids (Tuberculostearic acid).
  71. 71. Adenosine Deaminase (ADA) 􀂄 It is an enzyme of purine metabolism. The level of this enzyme is 10 times higher in lymphocytes (T cells >B cells) than in RBC. 􀂄 Whenever there is cell mediated immune response to an antigenic stimuli, the ADA levels are the highest. 􀂄 ADA is measured by the colorimetric method of Giusti.
  72. 72. enzymatic reaction is: Adenosine + H2O + ADA = Inosine + NH3 +ADA 􀂄 The amount of ammonia liberated is measured by the colorimetric method. Cut-off Sensitivity Specificity Pleural Fluid 50 IU/ml 95% 100% Ascitic Fliud 32.3 IU/ml 89% 98% CSF 9 IU/ml 100% 100%
  73. 73. Bromide Partition Test 􀂄 The partition of bromide ion between serum and CSF after a loading dose reflects the integrity of the blood brain barrier. 􀂄 Either by direct chemical measurement or by using an isotopic tracer, the ratio of bromide in serum to that in CSF can be estimated. 􀂄 Values <1.6 are characteristic of TBM.
  74. 74. In different studies the sensitivity and specificity of this test has been found to be near 90%.* 􀂄 It may be false +ve in herpes simplex, listeria, mumps, measles, pyogenic meningitis and hypothyroidism. 􀂄 With the availability of better tests, this test has been given up. *Taylor J et al. J Clin Microbiol 1999; 34: 56-59
  75. 75. Tuberculostearic Acid (TBSA) 􀂄 TBSA is found in the cell wall of mycobacterium. 􀂄 It is identified by gas chromatography or mass spectrophotometry. 􀂄 It is a costly investigation and requires complex analytical equipment. (Seldom used) Sensitivity >95%,Specificity>99%.* 􀂄 *French M et al. J Clin Microbiol 1998; 54: 987-990
  76. 76. CT Scan and MRI Scan in the diagnosis of TB 􀂄 The advent of CT and MRI imaging in the last two decades has redefined the approach in analysis of various diseases including TB.* 􀂄 CT and MRI have shown several advantages over conventional radiology in early diagnosis and follow-up of TB in different parts of the body. *Buxi TBS Indian J Pediatr 2002;69:965-972
  77. 77. Pulmonary TB : Lobar Pneumonia 􀂄 CT is superior than plain CXR in picking up the consolidation, atelectasis and the hilar LN thereby making the diagnosis easy. 􀂄 MRI reveals some of these changes, however, CT is the diagnostic modality of choice in such cases. 􀂄 Bronchopneumonia 􀂄 On CT it is usually B/L and widespread, not always symmetrical involvement of lungs. 􀂄
  78. 78. Hilar and Mediastinal Lymphadenopathy CT and MRI depict the hilar and mediastinal LN equally well. 􀂄 Calcification in the nodes is however better seen on CT. 􀂄 Necrosis is seen as focal areas of low attenuation on a CECT. 􀂄 On MRI focal necrosis is seen as areas of increased signal intensity on T2W images. 􀂄 EBTB 􀂄 HRCT is sensitive in the detection of early endobronchial spread of disease. 􀂄
  79. 79. Miliary TB 􀂄 Earliest form of miliary TB is detectable on HRCT. 􀂄 Coalescing nodules result into patchy irregular opacities and HRCT shows this variation effectively and has been described as “snowstorm appearance”. 􀂄 HRCT shows cavitation, which is not evident on plain CXR. Pleural Effusion 􀂄 􀂄 CT is sensitive to diagnose and define even minimal pleural effusion/pleural calcification. 􀂄 Pleural fluid is seen on inversion recovery MR images as areas of increased signal intensity along the inner aspects of the chest wall.
  80. 80. Skeletal TB Pott’s Disease (vertebral TB) 􀂄 CT and MRI helps in demonstrating a small focus of vertebral body involvement and defining the extent of the disease. 􀂄 CT/MRI help to evaluate TB involving the craniovertebral junction, sacro-iliac joint and posterior appendages. 􀂄 They are also helpful in assessment of spinal canal encroachment , posterior element involvement and in deciding the surgical approach. 􀂄
  81. 81. GIT TB Strictures of the small bowel, mucosal edema and thickening are well visualized on CT. 􀂄 MRI depicts the para-aortic, aortocaval and mesentric lymph nodes effectively. 􀂄 GUT TB 􀂄 Various patterns of hydronephrosis may be seen at MR urography. 􀂄 MRI helps to differentiate macronodular TB lesions from the other mass lesions. 􀂄
  82. 82. Boehme C, NEJM, 2010
  83. 83. CXR Findings  Primary TB:   Reactivated TB:   Lower or middle lobe infiltrates Apical infiltrates/cavitation Latent TB: Usually normal  Nodules in hilar area or upper lobes  Pleural scarring/thickening 
  84. 84. Transmission     Transmitted by airborne particles 1-5 microns in size Ease of transmission depends on duration and proximity of contact as well as the number of bacteria excreted Infection can result from only 1-5 bacteria entering a terminal alveolus Only those with active pulmonary TB are infectious
  85. 85. *M tuberculosis is transmitted via airborne droplet nuclei that are produced when persons with pulmonary or laryngeal TB cough, sneeze, speak, or sing . * Droplet nuclei may be produced by aerosol treatments, sputum induction,aerosolization during bronchoscopy, and through manipulation of lesions or processing of tissue or secretions in the hospital or laboratory.
  86. 86. Pathogenesis – Inhalation -> phagocytosis by alveolar macrophages – Bacterial multiplication occurs intracellularly – Lymphatic spread to regional lymph nodes or hematogenous dissemination – Immune response results in granuloma formation (containment of infection) – Cell death in the granuloma results in caseous necrosis – Bacteria can remain dormant in the granuloma
  87. 87. Pathogenesis – Medical conditions that increase risk for active TB: Chronic renal failure  Diabetes mellitus  Silicosis  Leukemias/lymphomas  Carcinoma of the head/neck or lung  Weight loss > 10% of ideal body weight  Gastrectomy/jejunoileal bypass 
  88. 88. Primary pulmonary tuberculosis *The first infection with tubercle bacillus. Includes the involvement of the draining lymph nodes in addition to the initial lesion(Ghon).
  89. 89. Clinical features: Majority: symptomless.(specially in young adults) Brief febrile illness. Loss of appetite. Failure to gain weight in children. Cough is not unusual and may mimic paroxysm of whooping cough.
  90. 90. Physical signs: •May be normal, •Crepitation may be heard. •Primary lesion could be heard. •Segmental or lobar collapse may occur.
  91. 91. Radiological features: •Lymphadenoathy: hilar lymph nodes are most commonly involved rarely paratracheal.Calciflcation of the nodes may occur. • Pulmonary componant: ( mainly in adults) segmental or lobar consolidation or obstructive emphysema. •Resolution of radiological shadow 6m2ys.
  92. 92. Diagnosis: *Vague ill health with history of contact. * X-ray. *Tuberclin test: is usually strongly positive. *Sputum and gastric lavage for direct smear and culture helpful in 20-25% of cases. * DNA amplification: PCR.
  93. 93. Post primary pulmonary tuberculosis The most important type of tuberculosis because it is the most frequent and smear positive sputum is the main source of infection responsible for the persistence of the disease in the community.
  94. 94. Source; 1. Direct progression of the primary lesion. 2. Reactivation of the quiescent primary or post primary. 3. Exogenous infection.
  95. 95. Predisposing factors for reactivation: 1. Malnutrition. 2. Poor housing and overcrowding. 3. Steroid and other immunosuppressive drugs. 4. Alcoholism. 5.Other diseases: HIV malignancy, lymphomas , Leukaemia,Diabetes.
  96. 96. Clinical features: Mainly in middle aged and elderly. A-Symptoms: 1. May be no symptoms, or just mild debility. Gradual onset of symptoms over weeks or months. 2. General malaise. 3. Loss of appetite, loss of weight. 4. Febrile course. 5. Night sweating. 6. Cough with or without sputum. 7. Sputum could be mucoid, purulent or blood stained. 8. Could be presented with frank haemoptysis. 9. Tuberculous pneunonia.
  97. 97. B-Signs: 1. May be no signs. 2. Pallor, cachexia. 3. Fever. 4. Post tussive crepitations on the apices. 5. Signs of Consolidation. 6. Signs of fibrosis. 7. Signs of cavitary lesion. 8. Localised wheezes in endobronchial tuberculosis
  98. 98. Lymph nodes Retrosternal Prevascular Retrocaval Aortic window Carinal Subcarinal Hilar Z-esophageal Circm-cardiac Anatomic Considerations 3 3
  99. 99. Lymph nodes Anatomic Considerations 5 Retrosternal Prevascular Retrocaval Aortic window Carinal Subcarinal Hilar Z-esophageal Circm-cardiac 6
  100. 100. Anatomic Considerations Lymph nodes 7 Retrosternal Prevascular Retrocaval Aortic window Carinal Subcarinal Hilar Z-esophageal Circm-cardiac 7 8 9
  101. 101. Radiology: 1. Bilateral upper zone fibrotic shadows: with shift of trachea, mediastinum, distortion of fissures and diaphragm, and elevation of the pulmonary hila. 2. Soft confluent shadows of exudative lesion (D.D pneumonia) 3 Calcification. 4. Cavitation. 5. Tuberculoma. 6. Hilar and paratracheal lymph node enlargement may be present.
  102. 102. Radiological classification: 1.Minimal: slight or moderate opacity. No cavity. Extent not more than space above 2nd costocondral junction. 2. Moderately advanced: In one or both lungs. slight or moderate opacity, extent equivalent to volume of one lung. Dense confluent shadow equivalent to one third the volume of one lung. Diameter of cavities not more than 4 cm. 3. Far advanced: Any lesion>the moderately advanced.
  103. 103. Diasnosis: 1) Clinical 2) Plain X-ray. 3) Sputum Examination: direct smear and culture (very important). 4) Other samples: Gastric aspirate, laryngeal swab, fiberoptic specimens (wash,brush,biopsy),transtracheal spirate. 5 Polymerase chain reaction.) 6) Tuberclin test: mainly strongly positive 7) Others White blood cells if normal favour the diagnosis ESR may be elevated. Normocytic normochromic anaemia. CT may be useful in detecting small cavities, or calcification.
  104. 104. Miliary Tuberculosis Produced by acute dissemination of tubercle bacilli via the blood stream.The term miliary derives from the radiological picture of diffuse, discrete nodular shadows about the size of millet seed (2mm).
  105. 105. A- Classical form: Clinical features: Most common in infants and young children with acute or subacute febrile illness. In adults: the onset is insidious, gradual vague ill health. Malaise, Cough (usually dry), dyspnea. Night sweat is less common. Headache suggest associated tuberculous meningitis Chest examination is free, crepitations may be found. Hepatomegaly, splenomegaly, lymphadenopathy, neck rigidity may be found in rare cases.
  106. 106. Diasnosis: 1) Clinical. 2) Xray. 3) Choroidal tubercles in fundus examination 4) Tuberclin test not conclusive 5) Direct smear and culture of sputum if present. 6) Other samples as transtracheal aspirate, fiberoptic specimens may be obtained. 7) If failed to prove therapeutic trial for 2 weeks
  107. 107. Mycobacterium tuberculosis-latent bacilli are microorganisms that adapt to stressful conditions generated by the infected host against them. By slowing metabolism or becoming dormant, they may counterbalance these conditions and appear as silent to the immune system. Moreover, the dynamic turnover of the infected cells provokes a constant reactivation of the latent bacilli when the environmental conditions are favourable, or an activation after being dormant in necrotic and fibrotic lesions for a long period of time.
  108. 108. • • • • • Achalasia of esophagus Inhomogeneous cardiac density: Right half more dense than left Density crossing midline (right black arrow) Right sided inlet to outlet shadow Right para spinal line (left black arrow) Barium swallow below: Dilated esophagus
  109. 109. Dissecting Aneurysm *Mediastinal widening *Inlet to outlet shadow on left side *Retrocardiac: Intact silhouette of left heart margin *Pulmonary artery overlay sign: Density behind left lower lobe *Wavy margin
  110. 110. Treatment     Before 1940s: open air (sanatorium) 1946: streptomycin 1952: isoniazid 1970: rifampin
  111. 111. Antituberculous drugs: A. First line drugs; Isoniazide (INH) or H Rifampicin ( R ) Streptomycin ( S ) Ethamutol ( E ) Pyrizinamide ( Z ) B.Second line drugs : Thiacetazone (150mg) Para amino salicylic acid (10-20 g) Ethionamide (<50Kg, 750mg&>50Kg, Ig) Cycloserine 5-20mg/Kg) Kanamycin, Capreomycin, Viomycin (20mg/Kg max Ig) C.New drugs: Amikacin, Quinolones, Rifabutin, new macrolides, Amoxicillin-clavulinic acid. and
  112. 112. Drugs Dose Dose Adult Child Isoniazide (INH) or H 5 mg/Kg up to 12mg/Kg in miliary. 10 mg/Kg Rifampicin (R) lOmg /Kg <50Kg, 450mg >50Kg, 600mg 10-20mg Ethambutol (E) 25mg/Kg for two months, then 15mg/Kg <50Kg,1.5g 50-74Kg, 2g >75Kg, 2.5g 20mg/Kg (max Ig) Contraindi cated Adverse effect Pyrazinamie (Z) Streptomycin (S) Peripheral neuritis, hepatitis, hypersensitivity. Orange urine Flu like illness Hepatitis Hypersensitivity Blood dyscriasis. Retrobulbar neuritis 40mg/Kg Hepatotoxicity Hyperuricaemia 20mg/Kg Ototoxicity (vestibular) Nephrotoxicity Hypersensitivity
  113. 113. Drus regimens: according to WHO guidelines 1-New smear positive patient 2SRHZ/6HE(8months regimens)or 2SHE/10HE(12months regimens)or 2SRHZ/4RH (6 months regimen) 2-Previously treated smear positive patients 2SRHZE/1RHZE/5RHE (8month regimen) a sensitivity pattern is recommended. 3- Smear negative and extrapulmonary TB 2SHE/10HE (12 months regimen) 4- Chronic smear positive patient (Treated in hospital): a Sensitivity pattern is recommended to give special treatment regimen.
  114. 114. Corticosteroid Therapy in Tuberculosis Corticosteroid should never be given to patientswith tuberculosis unless they are receiving adequate antituberculous therapy Indications of steroids: *In very ill patient. *To control drug hypersensitivity. *In tuberculosis of serous sacs (pericarditis, peritonitis and pleural effusion). *In tuberculous meningitis. *Addison disease. *Genitourinary tuberculosis. *Occasionally to suppress lymph node enlargement.
  115. 115. Treatment of Active TB  Four drug regimen for first 2 months: INH 300 mg  Rifampin 600 mg  PZA 15-30 mg/kg  Ethambutol 15-25 mg/kg or streptomycin 15 mg/kg   Two drug regimen for next 4 months:   INH and rifampin If the TB is not resistant (or < 4% resistance in the community): INH, rifampin, and PZA for the first 2 months can be used
  116. 116. Treatment of Active TB  INH resistant TB: – Rifampin, PZA, and ethambutol for 6 months  Rifampin resistant TB: – INH, PZA, and streptomycin for 9 months or INH and ethambutol for 18 months  MDR/XDR TB: – Based on susceptibility patterns
  117. 117. Blumberg, HM; IDSA
  118. 118. Factors in Treatment of Latent TB  Age: Previously, low risk patients older than 35 were not treated – higher risk of druginduced hepatitis  “Decision to tuberculin test is a decision to treat”  Weigh risks/benefits of treatment in low risk patients   Liver disease:  End stage liver disease and active hepatitis are relative contraindications to treatment
  119. 119. Treatment of Latent TB    Efficacy of 90% if all the medications are taken 60-70% rates when the drugs are selfadministered Protective effect will last probably for life but at least 20 years
  120. 120. Treatment of Latent TB  Need to exclude active disease before treatment (avoids single drug therapy of active TB)   CXR – if changes consistent with TB, send AFB sputum culture Single drug therapy appropriate for latent TB – bacterial load much lower compared with active TB
  121. 121. Treatment of Latent TB  Regimens: – Isoniazid (INH) daily or twice weekly under directly observed therapy (esp. if adherence is an issue) 9 months of treatment is optimal  At least 6 months is needed  12 months if treatment is interrupted  – Rifampin daily 4 months of treatment  Alternative regimen for those exposed to an INH resistant patient 
  122. 122. Treatment of Latent TB  Regimens: – Rifampin/PZA for 2 months Similar in safety and efficacy to 12 month regimen of INH  No longer recommended due to hepatic toxicity (including liver failure leading to death) 
  123. 123. Treatment of Latent TB  Regimens: Multi-Drug Resistant TB – Therapy based on susceptibility pattern of the index case if information available – 2 drug therapy for 12 months PZA plus  Ethambutol or  Fluoroquinolone with anti-TB activity 
  124. 124. Treatment of Latent TB    If INH treatment is interrupted, an additional 3 months should be given If interruption is >3 months, re-start treatment If a treated person is re-exposed to someone with TB, repeat treatment is not needed unless the patient is HIV+
  125. 125. Treatment – Special Situations  HIV: Up to 20% of patients with CD4 counts < 200 can have a normal CXR with active TB – send sputum before treatment  Recent contact with someone with active TB: treat regardless of PPD result  Anergy testing not recommended  Extrapulmonary TB more common  Immune reconstitution  Same treatment regimens (except rifabutin instead of rifampin for patients on PIs) 
  126. 126. Treatment – Special Situations  Pregnancy: – No evidence that PPD testing is harmful – INH: not teratogenic; hepatotoxicity may be more likely – Rifampin: generally considered safe – reports of hemorrhage in the newborn – Ethambutol: okay – Streptomycin: avoid (congenital deafness) – PZA: no published safety data – Breast-feeding is not contraindicated
  127. 127. Treatment – Special Situations  Pregnancy: – Active TB – treat – Latent TB (immunocompetent host) – defer therapy until after delivery – Latent TB (HIV or recent converter) – immediate therapy with INH
  128. 128. Monitoring on Treatment  INH: Side effects Abdominal pain, nausea, vomiting  Dark urine  Icterus  Easy bruising/bleeding  Arthralgias  Rash  Paresthesias/weakness – peripheral neuropathy is less likely with pyridoxine  Anorexia/fatigue 
  129. 129. Monitoring on Treatment  INH – Elevated transaminases in 10-20% of cases – especially with EtOH – Should be withheld if transaminases increase more than 3x the upper limit of normal when associated with symptoms or 5x the upper limit of normal in asymptomatic patients
  130. 130. Monitoring on Treatment  Rifampin: Side effects – GI upset – Thrombocytopenia – Hepatitis – Flu-like syndrome – if taken irregularly – Multiple drug interactions – Orange bodily secretions due to excretion
  131. 131. Monitoring on Treatment  PZA: Side effects – – – –  GI upset Hepatitis Arthralgias Hyperuricemia – acute gout uncommon Ethambutol: – Optic neuritis: reversible decreased red-green color perception and visual acuity – Not hepatotoxic
  132. 132. Adherence   Decreases with duration of therapy whereas efficacy increases with length of treatment Factors: Side effects  Complexity of regimen (active TB)  Perception (especially in latent TB)   Directly Observed Therapy – especially in twice weekly regimens
  133. 133. Infection Prevention  If active pulmonary TB is suspected: – AFB isolation – Negative pressure – Particulate respirator masks  Isolation not required for: – Latent TB – Extrapulmonary TB
  134. 134. Infection Prevention  Isolation can be discontinued: – If AFB smears x 3 are negative – An alternative diagnosis is made  If patient has active TB, then: – After 2 weeks of effective therapy – Resolution of cough, fever – Negative or “less positive” AFB smears
  135. 135. S Curve of Golden When there is a mass adjacent to a fissure, the fissure takes the shape of an "S". The proximal convexity is due to a mass, and the distal concavity is due to atelectasis. Note the shape of the transverse fissure. This example represents a RUL mass with atelectasis
  136. 136. Definitions MDR-TB = Strains resistant to at least INH and RIF (most important 1st-line drugs) XDR-TB = MDR TB strains with additional resistance to any fluoroquinolone and any of the 3 injectable second-line drugs (amikacin, kanamycin, capreomycin) TDR, XXDR = Resistance to all drugs (not standardised defin) TB with any MDR TB drug resistance TDR/XXDR TB XDR TB
  137. 137. XDR= HR + 1 FQ + 1 Injectable (KM or AMK or CM) 1st-line oral •INH Injectables •RIF •SM Fluoroquinolones •PZA •KM •Cipro •EMB •AMK •Oflox •ETA/PTA •Levo •PASA •CM •(Rfb) •Moxi •(Gati) Oral bacteriostatic 2nd line •CYS Unclear efficacy Not routinely recommended, efficacy unknown, e.g., amoxacillin/clavulanic acid, clarithromycin, clofazamine, linezolid, inmipenem/cilastatin, 204 high dose isonizid

×